Eyeing Novartis deal, Akcea trumpets lipoprotein drug dataIonis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with Share XEyeing Novartis deal, Akcea trumpets lipoprotein drug datahttps://pharmaphorum.com/news/eyeing-novartis-deal-akcea-trumpets-lipoprotein-drug-data/
Entresto tops mainstay ACE inhibitor in heart failure trialTwo years ago, Novartis launched a big trials programme for its heart failure drug Entresto in the hope Share XEntresto tops mainstay ACE inhibitor in heart failure trialhttps://pharmaphorum.com/news/entresto-tops-mainstay-ace-inhibitor-in-heart-failure-trial/
Merck gets FDA okay for Keytruda as liver cancer therapyMerck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular Share XMerck gets FDA okay for Keytruda as liver cancer therapyhttps://pharmaphorum.com/news/merck-gets-fda-okay-for-keytruda-as-liver-cancer-therapy/
China’s BeiGene delays US filing for rival to ImbruvicaBeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s Share XChina’s BeiGene delays US filing for rival to Imbruvicahttps://pharmaphorum.com/news/chinas-beigene-delays-us-filing-for-rival-to-imbruvica/
BMS, AbbVie get FDA OK for new myeloma regimenBristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they Share XBMS, AbbVie get FDA OK for new myeloma regimenhttps://pharmaphorum.com/news/bms-abbvie-get-fda-ok-for-new-myeloma-regimen/
Daiichi Sankyo claims speedy review for AML drug in EuropeJapan’s Daiichi Sankyo is looking at a reduced review time for its acute myeloid leukaemia (AML) drug quizartinib Share XDaiichi Sankyo claims speedy review for AML drug in Europehttps://pharmaphorum.com/news/daiichi-sankyo-speedy-review-aml-drug-europe/
Novartis says $4m price is reasonable for SMA gene therapyNovartis says it thinks its one-off gene therapy for spinal muscular atrophy (SMA) could deliver value for money Share XNovartis says $4m price is reasonable for SMA gene therapyhttps://pharmaphorum.com/news/novartis-says-4m-price-is-reasonable-for-sma-gene-therapy/
FDA panel backs Sage’s novel antidepressant but turns down Alkermes’Sage’s Zulresso (brexanolone) is on course for approval for postnatal depression in the US after a positive vote Share XFDA panel backs Sage’s novel antidepressant but turns down Alkermes’https://pharmaphorum.com/news/fda-panel-backs-sages-novel-antidepressant-but-turns-down-alkermes/
Novo Nordisk staff cull swells to 1,300Novo Nordisk has raised the number of staff it will shed this year in order to invest more Share XNovo Nordisk staff cull swells to 1,300https://pharmaphorum.com/news/novo-nordisk-staff-cull-swells-to-1300/
